Cargando…
Phase I dose escalation pharmacokinetic assessment of intravenous humanized anti-MUC1 antibody AS1402 in patients with advanced breast cancer
INTRODUCTION: MUC1 is a cell-surface glycoprotein that establishes a molecular barrier at the epithelial surface and engages in morphogenetic signal transduction. Alterations in MUC1 glycosylation accompany the development of cancer and influence cellular growth, differentiation, transformation, adh...
Autores principales: | Pegram, Mark D, Borges, Virginia F, Ibrahim, Nuhad, Fuloria, Jyotsna, Shapiro, Charles, Perez, Susan, Wang, Karen, Schaedli Stark, Franziska, Courtenay Luck, Nigel |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2790853/ https://www.ncbi.nlm.nih.gov/pubmed/19811637 http://dx.doi.org/10.1186/bcr2409 |
Ejemplares similares
-
Population pharmacokinetics of the humanised monoclonal antibody, HuHMFG1 (AS1402), derived from a phase I study on breast cancer
por: Royer, B, et al.
Publicado: (2010) -
Safety, Tolerability and Pharmacokinetics of Single-Dose Oral SYHA1402 in Healthy Chinese Subjects
por: Liang, Beibei, et al.
Publicado: (2023) -
Nezahualcóyotl, Acolmiztli, 1402-1472
por: Alva Ixtlilxóchitl, Fernando de, 1402-1472
Publicado: (1972) -
MYL-1402O: A Bevacizumab Biosimilar
por: Lee, Arnold
Publicado: (2021) -
A pharmacokinetics study of proposed bevacizumab biosimilar MYL-1402O vs EU-bevacizumab and US-bevacizumab
por: Hummel, Matthew, et al.
Publicado: (2021)